We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note
Read MoreHide Full Article
DaVita HealthCare (DVA - Free Report) closed at $126.11 in the latest trading session, marking a -1.2% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 0.22% for the day. At the same time, the Dow added 0.06%, and the tech-heavy Nasdaq lost 0.52%.
Coming into today, shares of the kidney dialysis provider had lost 8.03% in the past month. In that same time, the Medical sector lost 6.22%, while the S&P 500 lost 1.66%.
Investors will be eagerly watching for the performance of DaVita HealthCare in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on May 2, 2024. It is anticipated that the company will report an EPS of $1.96, marking a 24.05% rise compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $3.01 billion, up 4.78% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $9.23 per share and revenue of $12.56 billion. These totals would mark changes of +8.97% and +3.47%, respectively, from last year.
Any recent changes to analyst estimates for DaVita HealthCare should also be noted by investors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Right now, DaVita HealthCare possesses a Zacks Rank of #2 (Buy).
From a valuation perspective, DaVita HealthCare is currently exchanging hands at a Forward P/E ratio of 13.82. Its industry sports an average Forward P/E of 20.13, so one might conclude that DaVita HealthCare is trading at a discount comparatively.
It's also important to note that DVA currently trades at a PEG ratio of 1.14. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical - Outpatient and Home Healthcare industry currently had an average PEG ratio of 1.72 as of yesterday's close.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. This group has a Zacks Industry Rank of 93, putting it in the top 37% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note
DaVita HealthCare (DVA - Free Report) closed at $126.11 in the latest trading session, marking a -1.2% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 0.22% for the day. At the same time, the Dow added 0.06%, and the tech-heavy Nasdaq lost 0.52%.
Coming into today, shares of the kidney dialysis provider had lost 8.03% in the past month. In that same time, the Medical sector lost 6.22%, while the S&P 500 lost 1.66%.
Investors will be eagerly watching for the performance of DaVita HealthCare in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on May 2, 2024. It is anticipated that the company will report an EPS of $1.96, marking a 24.05% rise compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $3.01 billion, up 4.78% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $9.23 per share and revenue of $12.56 billion. These totals would mark changes of +8.97% and +3.47%, respectively, from last year.
Any recent changes to analyst estimates for DaVita HealthCare should also be noted by investors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Right now, DaVita HealthCare possesses a Zacks Rank of #2 (Buy).
From a valuation perspective, DaVita HealthCare is currently exchanging hands at a Forward P/E ratio of 13.82. Its industry sports an average Forward P/E of 20.13, so one might conclude that DaVita HealthCare is trading at a discount comparatively.
It's also important to note that DVA currently trades at a PEG ratio of 1.14. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical - Outpatient and Home Healthcare industry currently had an average PEG ratio of 1.72 as of yesterday's close.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. This group has a Zacks Industry Rank of 93, putting it in the top 37% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.